📊 This is a company profile preview from Tablestat.com Request a Free Trial Now

Company profile: Vaxart

1.1 - Company Overview

Vaxart Logo

Vaxart

Headquarter: United States
Founded: 20XX🔒
Employees: 100-500🔒

Company description

  • Provider of oral vaccine pills and vaccine technology for infectious diseases, including COVID-19 (Phase II, room-temperature stable for easier global distribution), norovirus (Phase 1), influenza (Phase 1 completed for H1N1 and influenza B), RSV (targeting vulnerable populations), and an HPV therapeutic vaccine for types 16 and 18, built on the VAAST™ platform using Ad5 to deliver antigens and adjuvants to mucosal cells.

Products and services

  • VAAST™ Platform: A proprietary system that uses adenovirus type 5 to deliver vaccine antigens and adjuvants directly to mucosal cells, enabling diverse oral vaccines
  • COVID-19 Vaccine Pill: A room-temperature-stable oral pill that protects against COVID-19, currently in Phase II clinical trials, facilitating easier global distribution
  • Norovirus Vaccine Pill: A clinical-stage oral pill targeting norovirus, with Phase 1 studies showing it is well tolerated and generates robust immune responses in recipients

Key contacts

🔒
🔒

Financial details

🔒

1.2 - Competitors and similar companies to Vaxart

Replimune Logo

Replimune

HQ: United States Website
  • Description: Provider of next-generation oncolytic immunotherapies for cancer, developing proprietary products that enhance direct anti-tumor effects of selective virus replication and boost immune responses to tumor antigens. Products include RP1 (HSV-1 strain with immune-activating transgenes), RP2 (anti-CTLA-4 antibody targeting immunologically silent tumors to enhance tumor killing and immune response), and RP3 (CD40L and 4-1BBL ligands).
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Replimune company profile →
Maverick Therapeutics Logo

Maverick Therapeutics

HQ: United States Website
  • Description: Provider of T cell immunotherapies for solid tumor cancers, developing breakthrough treatments with improved safety and efficacy via COBRA, the most advanced bispecific T cell engaging platform in its class designed to safely target solid tumors.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Maverick Therapeutics company profile →
GT Biopharma Logo

GT Biopharma

HQ: United States Website
  • Description: Provider of TriKE immunotherapy technology that bridges natural killer cells to cancer cells to boost anti-tumor responses. Pipeline includes GTB-3550 for CD33+ leukemias (AML, high-risk MDS), GTB-3650 using camelid nanobodies for CD33+ leukemias, and GTB-5550, GTB-4550, GTB-6550 for B7H3, PD-L1, and HER2 positive solid tumors.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full GT Biopharma company profile →
MinervaX Logo

MinervaX

HQ: Denmark Website
  • Description: Provider of a biotechnology solution developing a novel vaccine against Group B Streptococcus (GBS) using a fusion protein shown to elicit protective immunity; offering the AlpN GBS Vaccine candidate designed for pregnant women and older adults to prevent GBS infections and likely protect against many clinically relevant GBS strains.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full MinervaX company profile →
Grid Therapeutics Logo

Grid Therapeutics

HQ: United States Website
  • Description: Provider of AI-driven platforms and therapeutics for cancer, including GT103, a human-derived antibody targeting a tumor-specific epitope for lung and other cancers. Offerings include high-throughput antibody discovery without prior protein knowledge, an AI-driven data warehouse, computational biology tools, a tumor vaccine design program, and a Phase 1b NSCLC study of GT103.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Grid Therapeutics company profile →
🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒
🔒
🔒
🔒 View all strategic buyers with complete profiles
Start Free Trial →

2.2 - Strategic buyer groups for Vaxart

🔒

Buyer group 1: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 2: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 3: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to Vaxart

2.2 - Growth funds investing in similar companies to Vaxart

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for Vaxart

4.2 - Public trading comparable groups for Vaxart

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to Vaxart

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA
🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About Vaxart

What does Vaxart do?

Vaxart is a provider of oral vaccine pills and vaccine technology for infectious diseases, including COVID-19 (Phase II, room-temperature stable for easier global distribution), norovirus (Phase 1), influenza (Phase 1 completed for H1N1 and influenza B), RSV (targeting vulnerable populations), and an HPV therapeutic vaccine for types 16 and 18, built on the VAAST™ platform using Ad5 to deliver antigens and adjuvants to mucosal cells.

Who are Vaxart's competitors?

Vaxart's competitors and similar companies include Replimune, Maverick Therapeutics, GT Biopharma, MinervaX, and Grid Therapeutics.

Where is Vaxart headquartered?

Vaxart is headquartered in United States.

How many employees does Vaxart have?

Vaxart has 1,000 employees 🔒.

When was Vaxart founded?

Vaxart was founded in 2010 🔒.

What sector and industry vertical is Vaxart in?

Vaxart is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for Vaxart

Who are the top strategic acquirers in Vaxart's sector and industry

Top strategic M&A buyers and acquirers in Vaxart's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for Vaxart?

Top strategic M&A buyers groups and sectors for Vaxart include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in Vaxart's sector and industry vertical

Which are the top PE firms investing in Vaxart's sector and industry vertical?

Top PE firms investing in Vaxart's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in Vaxart's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in Vaxart's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in Vaxart's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to Vaxart include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in Vaxart's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for Vaxart?

The key public trading comparables and valuation benchmarks for Vaxart include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for Vaxart for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for Vaxart with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in Vaxart's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for Vaxart with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in Vaxart's' sector and industry vertical?

Access recent funding rounds and capital raises in Vaxart's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for Vaxart